Cargando…

Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Cytomegalovirus (CMV) retinitis is a rare end-organ disease of CMV infection and is a marker of severe immunosuppression, especially in human immunodeficiency virus (HIV)-positive patients. In multiple myeloma (MM) patients, CMV retinitis has been reported in the post-transplant setting, with an inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zu, Cheng, Xu, Yufeng, Wang, Yiyun, Zhang, Mingming, Zhao, Houli, Fang, Xiaoyun, Huang, He, Hu, Yongxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870699/
https://www.ncbi.nlm.nih.gov/pubmed/35200544
http://dx.doi.org/10.3390/curroncol29020044
_version_ 1784656820417069056
author Zu, Cheng
Xu, Yufeng
Wang, Yiyun
Zhang, Mingming
Zhao, Houli
Fang, Xiaoyun
Huang, He
Hu, Yongxian
author_facet Zu, Cheng
Xu, Yufeng
Wang, Yiyun
Zhang, Mingming
Zhao, Houli
Fang, Xiaoyun
Huang, He
Hu, Yongxian
author_sort Zu, Cheng
collection PubMed
description Cytomegalovirus (CMV) retinitis is a rare end-organ disease of CMV infection and is a marker of severe immunosuppression, especially in human immunodeficiency virus (HIV)-positive patients. In multiple myeloma (MM) patients, CMV retinitis has been reported in the post-transplant setting, with an incidence lower than 0.2%, and in patients receiving lenalidomide. Here, we describe the first case of CMV retinitis in myeloma patients following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T (BCMA CAR-T) cell therapy. In addition to CMV, the patient developed multiple infections including a mouth ulcer, pneumonia, and fungal enteritis. While the complete remission (CR) status of MM was maintained, he regained a visual acuity of 20/1000 after appropriate ophthalmologic treatment. This single case illustrates the potential of BCMA CAR-T therapy to induce profound humoral immunosuppression, and demonstrates an imperative need for an established standard of monitoring and prophylaxis of post-CAR-T infections.
format Online
Article
Text
id pubmed-8870699
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88706992022-02-25 Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma Zu, Cheng Xu, Yufeng Wang, Yiyun Zhang, Mingming Zhao, Houli Fang, Xiaoyun Huang, He Hu, Yongxian Curr Oncol Case Report Cytomegalovirus (CMV) retinitis is a rare end-organ disease of CMV infection and is a marker of severe immunosuppression, especially in human immunodeficiency virus (HIV)-positive patients. In multiple myeloma (MM) patients, CMV retinitis has been reported in the post-transplant setting, with an incidence lower than 0.2%, and in patients receiving lenalidomide. Here, we describe the first case of CMV retinitis in myeloma patients following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T (BCMA CAR-T) cell therapy. In addition to CMV, the patient developed multiple infections including a mouth ulcer, pneumonia, and fungal enteritis. While the complete remission (CR) status of MM was maintained, he regained a visual acuity of 20/1000 after appropriate ophthalmologic treatment. This single case illustrates the potential of BCMA CAR-T therapy to induce profound humoral immunosuppression, and demonstrates an imperative need for an established standard of monitoring and prophylaxis of post-CAR-T infections. MDPI 2022-01-24 /pmc/articles/PMC8870699/ /pubmed/35200544 http://dx.doi.org/10.3390/curroncol29020044 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Zu, Cheng
Xu, Yufeng
Wang, Yiyun
Zhang, Mingming
Zhao, Houli
Fang, Xiaoyun
Huang, He
Hu, Yongxian
Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
title Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
title_full Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
title_fullStr Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
title_full_unstemmed Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
title_short Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
title_sort cytomegalovirus retinitis and retinal detachment following chimeric antigen receptor t cell therapy for relapsed/refractory multiple myeloma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870699/
https://www.ncbi.nlm.nih.gov/pubmed/35200544
http://dx.doi.org/10.3390/curroncol29020044
work_keys_str_mv AT zucheng cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma
AT xuyufeng cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma
AT wangyiyun cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma
AT zhangmingming cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma
AT zhaohouli cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma
AT fangxiaoyun cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma
AT huanghe cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma
AT huyongxian cytomegalovirusretinitisandretinaldetachmentfollowingchimericantigenreceptortcelltherapyforrelapsedrefractorymultiplemyeloma